Table 2.
Chronology of diagnosis of HDP and SARS-CoV-2 infection
| N | Diagnosis SARS-CoV-2 |
Diagnosis HDP |
Delivery |
Neonatal antibodies SARS-CoV-2 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | SYN | GA | HDP | GA | interval SARS-HDP (w + d) | GA | interval DEL − SARS (w + d) | RT-PCR result nasopharyngeal* | RT-PCR result placenta tissue | CT RT-PCR placenta tissue | IgG | IgM + IgA | |
| Case | 1 | No | 8 + 0 | S-PE | 35 + 0 | 27 + 0 | 35 + 2 | 27 + 5 | Negative | Positive | 28.7 | Negative | N/A |
| Control | 2 | Mild | 9 + 3 | 38 + 5 | 29 + 2 | Negative | Negative | ≥40 | Negative | N/A | |||
| Case | 3 | No | 21 + 3 | S-PE | 36 + 3 | 15 + 0 | 36 + 5 | 15 + 2 | N/A | Positive | 33.5 | Negative | Negative |
| Control | 4 | Mild | 20 + 4 | 39 + 5 | 19 + 1 | N/A | Negative | ≥40 | Positive | Negative | |||
| Case | 5 | Mild | 24 + 4 | GHT | 37 + 1 | 12 + 3 | 39 + 5 | 15 + 4 | Negative | Positive | 32.4 | Positive | Negative |
| Control | 6 | Mild | 23 + 4 | 40 + 2 | 16 + 4 | Positive | Negative | ≥40 | Positive | Negative | |||
| Case | 7 | Mild | 24 + 6 | PE | 36 + 4 | 11 + 5 | 37 + 1 | 12 + 2 | Negative | Positive | 31.7 | Positive | Negative |
| Control | 8 | Mild | 25 + 1 | 39 + 2 | 14 + 1 | Negative | Positive | 33.9 | Positive | Negative | |||
| Case | 9 | Mild | 25 + 6 | GHT | 38 + 0 | 12 + 1 | 40 + 1 | 14 + 2 | Negative | Positive | 33.1 | Positive | Negative |
| Control | 10 | Mild | 25 + 5 | 41 + 2 | 15 + 3 | Negative | Negative | ≥40 | Positive | Negative | |||
| Case | 11 | Mild | 26 + 6 | S-PE | 35 + 0 | 8 + 1 | 36 + 5 | 9 + 6 | Negative | Positive | 23.1 | Positive | Negative |
| Control | 12 | Mild | 27 + 4 | 40 + 2 | 12 + 4 | Negative | Negative | ≥40 | Positive | Negative | |||
| Case | 13 | Mild | 29 + 4 | GHT | 35 + 3 | 5 + 6 | 39 + 6 | 13 + 2 | Negative | Negative | ≥40 | N/A | N/A |
| Control | 14 | No | 30 + 0 | 39 + 1 | 9 + 1 | Negative | Negative | ≥40 | N/A | N/A | |||
| Case | 15 | Severe | 30 + 0 | PE | 33 + 3 | 3 + 3 | 37 + 2 | 7 + 2 | N/A | Negative | ≥40 | Positive | Negative |
| Control | 16 | No | 29 + 4 | 41 + 0 | 11 + 3 | N/A | Negative | ≥40 | Positive | Negative | |||
| Case | 17 | No | 31 + 0 | GHT | 36 + 5 | 5 + 5 | 40 + 4 | 10 + 4 | Negative | Negative | ≥40 | N | N/A |
| Control | 18 | No | 31 + 2 | 39 + 6 | 8 + 4 | Negative | Negative | 39.5 | N | N/A | |||
| Case | 19 | No | 36 + 2 | PE | 37 + 5 | 1 +3 | 38 + 0 | 1 + 5 | Positive | Positive | 35.2 | N | N/A |
| Control | 20 | No | 36 + 4 | 40 + 2 | 3 + 4 | Positive | Negative | ≥40 | N | N/A | |||
| Case | 21 | No | 37 + 6 | PE | 37 + 6 | 0 + 0 | 38 + 1 | 0 + 2 | Negative | Positive | 33.9 | N | N/A |
| Control | 22 | No | 37 + 5 | 37 + 5 | 0 + 0 | Positive | Negative | ≥40 | Positive | Negative | |||
| Case | 23 | Severe | 38 + 3 | S-PE | 38 + 3 | 0 + 0 | 38 + 4 | 0 + 1 | Positive | Positive | 15.1 | Positive | Negative |
| Control | 24 | Mild | 38 + 3 | 38 + 3 | 0 + 0 | Positive | Negative | ≥40 | N | N/A | |||
| Case | 25 | No | 38 + 5 | PE | 38 + 5 | 0 + 0 | 38 + 6 | 0 + 1 | Positive | Negative | ≥40 | Negative | N/A |
| Control | 26 | No | 38 + 0 | 40 + 4 | 2 + 4 | Positive | Negative | ≥40 | Negative | N/A | |||
| Case | 27 | No | 39 + 0 | GHT | 39 + 0 | 0 + 0 | 39 + 2 | 0 + 2 | Positive | Negative | ≥40 | N/A | N/A |
| Control | 28 | No | 38 + 5 | 41 + 2 | 2 + 5 | Negative | Negative | ≥40 | N/A | N/A | |||
Syn, symptoms of SARS-COV-2, infection; GA, gestational age (week + days); HDP, hypertensive disorders of pregnancy; GHT, gestational hypertension; PE, preeclampsia; S-PE, severe preeclampsia; DELIV-PE (days):interval from diagnosis of COVID-19 to HDP, diagnosis, days; DELIV-SARS (days), interval from diagnosis of COVID-19 to delivery, days; CT, cycle threshold value RT-PCR; R, result; P, positive; N, negative; N/A, not available. The squares marked in gray color correspond to controls without HDP. * RT-PCR, was only performed if the latest negative RT-PCR, test was more than 3 months ago.